-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED's Orpathys-Tagrisso combination extends survival in Phase III lung cancer trial

PUBT·10/26/2026 00:02:52
Listen to the news
HUTCHMED's Orpathys-Tagrisso combination extends survival in Phase III lung cancer trial
  • HUTCHMED’s Phase III SAFFRON trial showed Orpathys with Tagrisso improved survival versus chemotherapy in previously treated advanced lung cancer.
  • The combination also delayed disease progression in patients with EGFR mutations and high MET overexpression or amplification following Tagrisso treatment.
  • Results were presented at ESMO Congress 2026 and simultaneously published in The New England Journal of Medicine.
  • The safety profile was manageable, with no new safety concerns identified.
  • The findings supported a US marketing application for the combination; submissions in Europe and Japan are progressing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382443), on October 26, 2026, and is solely responsible for the information contained therein.